Fabry disease and the skin: data from FOS, the Fabry outcome survey

被引:93
|
作者
Orteu, C. H. [1 ]
Jansen, T.
Lidove, O.
Jaussaud, R.
Hughes, D. A.
Pintos-Morell, G.
Ramaswami, U.
Parini, R.
Sunder-Plassman, G.
Beck, M.
Mehta, A. B.
机构
[1] Royal Free Hosp, Dept Dermatol, London NW3 2QG, England
[2] Royal Free Hosp, Dept Haematol, London NW3 2QG, England
[3] Ruhr Univ Bochum, Dept Dermatol, Bochum, Germany
[4] Hop Xavier Bichat, Dept Internal Med, Paris, France
[5] Hop Robert Debre, Dept Internal Med & Infect Dis, Reims, France
[6] Univ Hosp Germans Trias & Pujol, Dept Paediat, Badalona, Spain
[7] Addenbrookes Hosp, Dept Paediat, Cambridge, England
[8] Univ Milan, Dept Paediat, Monza, Italy
[9] Med Univ Vienna, Dept Med 3, Div Nephrol & Dialysis, Vienna, Austria
[10] Johannes Gutenberg Univ Mainz, Mainz, Germany
关键词
angiokeratoma; Fabry disease; hyperhidrosis; hypohidrosis; lymphoedema; telangiectasia;
D O I
10.1111/j.1365-2133.2007.08002.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Fabry disease (also known as Anderson-Fabry disease) is a rare, X-linked lysosomal storage disorder that is characterized by accumulation of globotriaosylceramide throughout a range of tissues in the body. Objectives To ascertain the prevalence and nature of cutaneous manifestations in patients with Fabry disease and to relate these to the severity of systemic manifestations of the disease. Methods We have documented the dermatological features of this disease with reference to data from 714 patients (345 males, 369 females) registered on the Fabry Outcome Survey (FOS), a multicentre European database. Results We confirm that the commonest disease manifestation is angiokeratoma. Overall, 78% of males and 50% of females had one or more dermatological abnormality, the commonest being angiokeratoma (66% males, 36% females), hypohidrosis (53% males, 28% females), telangiectasia (23% males, 9% females) and lymphoedema (16% males, 6% females). We demonstrate for the first time that the presence of cutaneous vascular lesions correlates with the severity of the systemic manifestations of the disease (pain, renal failure, cardiac disease, premature cerebrovascular disease) as assessed by a severity scoring system. Although the condition is X linked, there is a surprisingly high prevalence of abnormalities in females. Conclusions The FOS database is a useful epidemiological tool in establishing the variety and relevance of cutaneous manifestations in Fabry disease. The present study confirms that the presence of dermatological manifestations appears to be a marker of greater severity of systemic disease, which emphasizes the importance of the dermatological assessment of these patients.
引用
下载
收藏
页码:331 / 337
页数:7
相关论文
共 50 条
  • [41] Pregnancy Events in Females with Fabry Disease in the Fabry Outcome Survey
    Hughes, Derralynn
    Deegan, Patrick
    Romero, Barba
    Hollak, Carla
    Giugliani, Roberto
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S37 - S37
  • [42] Natural history of Fabry disease in females in the Fabry outcome survey
    Deegan, PB
    Baehner, AF
    Romero, MAB
    Hughes, DA
    Kampmann, C
    Beck, M
    JOURNAL OF MEDICAL GENETICS, 2006, 43 (04) : 347 - 352
  • [43] OPHTHALMOLOGICAL MANIFESTATIONS IN CHILDREN WITH FABRY DISEASE IN THE FABRY OUTCOME SURVEY
    Kalkum, G.
    Beck, M.
    Larroque, S.
    Parini, R.
    Pintos-Morell, G.
    Ramaswami, U.
    Rohrbach, M.
    Pitz, S.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2012, 35 : S94 - S94
  • [44] Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey
    Schaefer, E
    Mehta, A
    Gal, A
    ACTA PAEDIATRICA, 2005, 94 : 87 - 92
  • [45] Ophthalmological manifestations in Fabry disease children in the Fabry Outcome Survey
    Karabul, Nesrin
    Pitz, Susanne
    Kalkum, Gisela
    Pintos-Morell, Guillem
    Parini, Rossella
    Rohrbach, Marianne
    Ramaswami, Uma
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S60 - S60
  • [46] Patients with Fabry disease with cutaneous vascular lesions have higher disease severity scores and more multisystem involvement: data from 1354 patients registered on FOS, the Fabry Outcome Survey
    Dhoat, S.
    Orteu, C. H.
    Navarro, C.
    Lidove, O.
    Jansen, T.
    Clarke, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 : 45 - 45
  • [47] Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey (vol 36, pg 663, 2006)
    Hajioff, D.
    Hegemann, S.
    Conti, G.
    Beck, M.
    Sunder-Plassmann, G.
    Widmer, U.
    Mehta, A.
    Keilmann, A.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 (10) : 828 - 828
  • [48] Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey
    Lidove, O.
    Ramaswami, U.
    Jaussaud, R.
    Barbey, F.
    Maisonobe, T.
    Caillaud, C.
    Beck, M.
    Sunder-Plassmann, G.
    Linhart, A.
    Mehta, A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (09) : 1053 - 1059
  • [49] Fabry disease in children and response to enzyme replacement therapy: results from the fabry outcome survey
    Ramaswami, U.
    Parini, R.
    Pintos-Morell, G.
    Hartung, R.
    Kampmann, C.
    Beck, M.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 122 - 122
  • [50] Cardiac manifestations of Anderson-Fabry disease results from the international Fabry outcome survey
    Linhart, Ales
    Kampmann, Christoph
    Zamorano, Jose L.
    Sunder-Plassmann, Gere
    Beck, Michael
    Mehta, Atul
    Elliott, Perry M.
    EUROPEAN HEART JOURNAL, 2007, 28 (10) : 1228 - 1235